Ashtead D reaffirms guidance for revenue and capex

Ashtead D reaffirms guidance for revenue and capex

Cambridge, Mass.--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary fourth quarter and full year 2024 global net product revenues, as well as its 2025 combined net product revenue guidance and pipeline goals. The company reported full year 2024 net product revenues of $1,646 million for its key products, representing a 33% annual growth compared to 2023.

The company's 2025 combined net product revenue guidance ranges from $2,050 million to $2,250 million, reflecting a 31% full year growth compared to 2024. This includes a projected growth of 36% for the TTR franchise (ONPATTRO and AMVUTTRA) and 15% for the Rare franchise (GIVLAARI and OXLUMO).

Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam, stated, "Alnylam’s commercial and clinical achievements in 2024 position us very well for another transformative year in 2025, as we continue to evolve into a global, top-tier biotech company. We generated net product revenues for the year of over $1.6 billion, representing growth of 33% compared to 2023, at the high end of our revised guidance range, and demonstrating the strength of our underlying hATTR-PN and Rare businesses."

The company expects 2025 to be an important inflection point for its TTR franchise, with the potential launch of vutrisiran in ATTR-CM delivering significant topline growth. Alnylam also anticipates achieving non-GAAP profitability in 2025.

In addition to its strong financial performance, Alnylam has a robust clinical pipeline with multi-billion-dollar opportunities for sustainable growth. Key pipeline goals for 2025 include achieving FDA approval for vutrisiran in ATTR-CM, initiating Phase 3 studies for Nucresiran and Zilebesiran, and reporting interim results for Mivelsiran in Alzheimer’s disease.

Alnylam management will discuss its preliminary 2024 net product revenues, as well as 2025 goals and guidance during a webcast presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California tomorrow, Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET).

Historical data suggests that ALNY’s earnings announcements have historically delivered strong returns for investors. A backtest of earnings release date performance from 2022 to the present shows a positive impact on the stock, with a maximum return of 12.46% recorded during one event out of 15 occurrences. These results highlight the potential for meaningful price movements following key earnings disclosures.

References:
[1] https://www.businesswire.com/news/home/20250112711585/en/Alnylam-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2024-Global-Net-Product-Revenues-and-Provides-2025-Combined-Net-Product-Revenue-Guidance-and-Pipeline-Goals